文献速递白血病

初诊急性髓系白血病中突变TP53等位基因频率的预后与治疗影响

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2020-01-01

该回顾性研究分析了202例初诊TP53突变急性髓系白血病患者,接受阿糖胞苷或去甲基化药物为基础的一线治疗。多因素分析显示TP53mut VAF>40%独立关联更高的累积复发率、更差的无复发生存和总生存。VAF对结局的影响主要由阿糖胞苷治疗患者驱动,HMA治疗中VAF对OS无显著影响。

要点

  • TP53mut VAF>40%独立关联更高复发率、更差RFS和OS。
  • VAF对OS的影响仅见于阿糖胞苷方案,HMA方案中无显著差异。
  • VAF≤40%且接受阿糖胞苷方案者长期结局最佳,2年OS为38%。

核心结论

  • TP53mut VAF>40%是初诊TP53突变AML独立的不良预后因素,可辅助一线治疗选择。

研究设计与样本

  • 回顾性分析202例初诊TP53突变AML患者,均接受以阿糖胞苷或HMA为基础的一线治疗。

主要发现

  • HMA联合或不联合维奈克拉对OS无显著影响,在整体TP53突变人群及按VAF分层后均如此。
  • VAF≤40%患者中,较高剂量阿糖胞苷者OS更优;VAF>40%患者无论何种治疗OS均相似地差。

临床怎么用

  • 初诊TP53突变AML应检测TP53mut VAF,VAF>40%提示预后极差。
  • VAF≤40%患者可考虑以阿糖胞苷为基础的一线方案,尤其较高剂量阿糖胞苷。
  • VAF>40%患者无论阿糖胞苷或HMA方案OS均差,需探索更优策略。

局限性

  • 回顾性研究设计,样本量202例,结论需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TP53 mutations are associated with poor outcomes in acute myeloid leukemia (AML). The prognostic impact of mutant TP53 (TP53mut) variant allelic frequency (VAF) is not well established, nor is how this information might guide optimal frontline therapy. We retrospectively analyzed 202 patients with newly diagnosed TP53-mutated AML who underwent first-line therapy with either a cytarabine- or hypomethylating agent (HMA)-based regimen. By multivariate analysis, TP53mut VAF >40% was independently associated with a significantly higher cumulative incidence of relapse (P = .003) and worse relapse-free survival (P = .001) and overall survival (OS; P = .003). The impact of TP53mut VAF on clinical outcomes was driven by patients treated with a cytarabine-based regimen (median OS, 4.7 vs 7.3 months for VAF >40% vs ≤40%; P = .006), whereas VAF did not significantly affect OS in patients treated with HMA. The addition of venetoclax to HMA did not significantly affect OS compared with HMA without venetoclax, both in the entire TP53-mutated population and in patients stratified by TP53mut VAF. Among patients with TP53mut VAF ≤40%, OS was superior in those treated with higher-dose cytarabine, whereas OS was similarly poor for patients with TP53mut VAF >40% regardless of therapy. The best long-term outcomes were observed in those with 1 TP53 mutation with VAF ≤40% who received a frontline cytarabine-based regimen (2-year OS, 38% vs 6% for all others; P < .001). In summary, TP53mut VAF provides important prognostic information that may be considered when selecting frontline therapy for patients with newly diagnosed TP53-mutated AML.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Short NJ, Montalban-Bravo G, Hwang H, et al. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv. 2020. PMID: 33211826. doi:10.1182/bloodadvances.2020003120

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。